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An assay to quantify the phosphorylation products of zidovudine (AZT) in peripheral blood
mononuclear cells (PBMC) was developed. Extracts of PBMC were separated by high-perfor-
mance liquid chromatography. Eluted AZT mono- (MP), di- (DP), and triphosphate (TP) were
collected in separate portions. Treatment with alkaline phosphatase yielded equimolar amounts
of AZT, which after solid-phase enrichment were assayed by radioimmunoassay. Detection limit
was 0.1 pmol/f O" PBMC for each nucleotide. Recoveries of 102%-118% were observed. AZT
nucleotides were measured in samples from three patients receiving 250 mg of AZT every 12 h.
Intracellular concentrations of AZT-MP after 1-2 h ranged from 0.9 to 1.4 pmol/Hl" PBMC and
then declined to 0.3-1.1 pmol/LO" PBMC after 4 h. AZT-DP and AZT-TP reached concentra-
tions of 0.3-0.5 pmol/Iu" PBMC after 1-2 h and could not be detected after 4 h in any of the
three patients. Duplicate determinations deviated by <20%.
Zidovudine (3'-azido-3'-deoxythymidine; AZT) has been
shown to improve survival in patients with AIDS and ad-
vanced AIDS-related complex [I]. The compound is a thy-
midine analog that is efficiently converted intracellularly to
AZT-5'-monophosphate (AZT-MP) by thymidine kinase.
AZT-MP is then further phosphorylated by thymidylate ki-
nase to the 5'-diphosphate (DP) form and finally to AZT-5'-
triphosphate (AZT-TP) [2]. AZT-TP is assumed to be the
active form of the drug as it competitively inhibits viral re-
verse transcriptase [2-4] and further causes proviral DNA
chain termination [5].
Serum pharmacokinetics ofAZT have been studied exten-
sively [6]; however, no data about the extent and kinetics of
in vivo phosphorylation are available. To date the intracellu-
lar anabolism of AZT and of other dideoxynucleosides has
been examined only in vitro using radiolabeled compounds
[2, 7-9]. A detailed knowledge about the in vivo phosphory-
lation is important for several reasons. First, there is a docu-
mented variability of AZT phosphorylation in various cell
systems [8], and data from in vitro experiments cannot neces-
sarily be extrapolated to the in vivo situation. Second, interin-
dividual differences in drug metabolism are well known in
clinical medicine for a variety of compounds, and it is con-
ceivable that differences in phosphorylation may at least
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partly explain the observed differences in the toxicity profile
and the clinical and virologic response. Finally, a better un-
derstanding of the in vivo pools and pharmacokinetics of
intracellular AZT-TP might lead to improved drug schedules
for individual patients. Thus we developed a method to mea-
sure the intracellular anabolites ofAZT in whole blood from
patients treated with this drug.
Materials and Methods
Preparation ofcell extracts. From patients receiving 250 mg
of AZT every 12 h or from healthy human immunodeficiency
virus (HIV)-seronegative controls, peripheral blood mononu-
clear cells (PBMC) from 20 ml of heparinized venous blood
were separated by ficoll-hypaque density gradient centrifuga-
tion. Aliquots of plasma were stored frozen at - 20°C for subse-
quent determination of AZT concentrations by RIA. Cells were
washed twice with cold PBS and counted by trypan blue dye
exclusion. Nucleotides were extracted twice with 250 J,LI of 0.33
rnol/l perchloric acid.
After neutralization of combined extracts with trioctylamine-
freon [10], the ribonucleotides were degraded by adding 20 J,LI of
0.2 mol/I sodium periodate, followed after 2 min by 30 J,Ll of 3
mol/I glycine. After mixing, extracts were incubated at 40°C for
1 h: 2 J.LI of 1 mol/l rhamnose was then added, and the samples
were put on ice or stored frozen at - 20°C.
Separation ofAZT nucleotides. Aliquots of extracts (200 J.L1,
corresponding to 6.8-16.5 X 106 PBMC) were separated by ion
exchange high-performance liquid chromatography (HPLC) on
a 5-J.Lm column (250 X 4.6 mrn: Supelcosil LC-SAX; Supelco,
Bellefonte. PA). A linear gradient from 12 to 120 mmol/l potas-
sium dihydrogen phosphate (KH 2P04 ) was applied within 10
min at a flow rate of 2 nil/min. Three fractions of the eluate (4
ml each) containing the AZT-MP. AZT-DP, or AZT-TP. respec-
tively, were collected.
Collection periods were established by chromatographing a
mixture of all three AZT nucleotides using UV detection at 267
nm. Beginning and end times were extended by at least 0.2 and
0.5 min on the front and back side of the peaks. This standard
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solution was freshly prepared by adding 0.07 units of alkaline
phosphatase (bovine type I-S; Sigma, S1. Louis) to 100 ttl of4.25
ttmoljl AZT-TP (Burroughs Wellcome, Research Triangle Park,
NC). After each series of separations the column was flushed
with 400 mmoljl phosphoric acid for 10 min to avoid peak
broadening due to column aging.
Hydrolysis ofAZT nucleotides. After addition of I ml of 1
moljl TRIS, pH 8.8, and 17.5 units of alkaline phosphatase,
fractions were incubated at 37°C for 24 h.
Solid-phase extraction of AZT. Hydrolyzed samples were
loaded on to a SepPak C 18 cartridge (Waters, Milford, MA) pre-
conditioned with 5 ml of methanol followed by 10 ml of dis-
tilled water. After washing with 10 ml of distilled water, AZT
was eluted with 2 ml of methanol.
Quantification ofAZT. Methanol was removed by vacuum
centrifugation (Speed Vac; Savant, Farmingdale, NY). The resi-
due was reconstituted in 200 ttl of RIA buffer. Amounts ofAZT
were determined by RIA (ZDV-Trac RIA; Incstar, Stillwater,
MN) according to the manufacturer's instructions. Standard
samples containing 1.1, 2.3, 4.6, 10, 20, 76, and 272 pmol of
AZT- TP in 200 ttl of distilled water were assayed in duplicate as
described for neutralized extracts. Calibration curves were con-
structed by plotting RIA counts against logarithms of standard
amounts. Results of unknown samples were normalized to 106
PBMC based on cell counts and volumes of extracts.
Determination ofanalytical recovery. Blood samples from an
untreated control were processed as described above, except
that known amounts of AZT -TP were added to the cell pellet
before perchloric acid extraction.
Cell cultures. PBMC (20 X 106 ) from a healthy HIV-sero-
negative blood donor were cultured for 24 h in 20 ml of RPM I
1640 medium (GIBCO BRL, Basel, Switzerland) supplemented
with 20% fetal bovine serum (Inotech, Wohlen, Switzerland)
and 10% interleukin-2 (200 units/rnl; Boehringer Mannheim,
Mannheim, Germany) in the presence of 2 ttmol/l eH]AZT
(500 dpm/pmol; cultures I and II) or 2 ttmoljl cold AZT (cul-
ture III). Antibiotics were omitted. Cells were collected from the
same blood donor for all three batches. Thereafter, cells were
harvested by centrifugation at 600 g for 10 min (cultures I and
III) or by ficoll separation (culture II). AZT nucIeotides in cell
extracts were quantified in duplicate by liquid scintillation
counting of HPLC eluates (cultures I and II) [I I] or by the
method described above (culture Ill).
Results
Log-logit transformed calibration curves obtained with
AZT-TP were linear from 1.1 to 272 pmol (r < -.990).
Lower amounts were not detectable. Analytical recoveries
from blank PBMC spiked with known amounts of AZT-TP
are shown in table 1. Duplicate determinations deviated by
<15%.
In PBMC cultured in the presence of 2 ~mol/l [3H]AZT
for 24 h, concentrations ofAZT-MP, AZT-DP, and AZT-TP
were 193, 1.3, and 2.0 pmolj 106 PBMC, respectively, after
ficoll-hypaque density-gradient centrifugation. If cells were
Table 1. Recovery from cell extracts spiked with zidovudine tri-
phosphate.
Zidovudine (pmol/ I06 peripheral
blood mononuclear cells)
Spiked Found % recovery
0.20 0.23 n s
0.50 0.54 108
1.4 1.5 107
2.0 2.4 118
5.0 5.1 102
NOTE. Data are means of duplicate determinations.
harvested by simple centrifugation, concentrations of 215,
1.7, and 1.6 pmolj 106 PBMC were found. PBMC of the same
donor treated under identical conditions but with unlabeled
AZT yielded concentrations of 198 pmol/ I06 PBMC for
AZT-MP, 1.8 pmol/Iu'' PBMC for AZT-DP, and 2.4 pmolj
106 PBMC for AZT-TP by RIA. These results rule out exces-
sive loss of AZT nucIeotides during sample preparation.
AZT-MP, -DP, and -TP were well separated by HPLC.
Mean retention times of 5.38, 7.87, and 9.49 min, respec-
tively, were observed, with only minor run-to-run variability
within the same day (SO < O. I min).
Blood samples were obtained from three patients on long-
term oral therapy with 250 mg of AZT every 12 h. AZT
nucleotides were determined before and I, 2, and 4 h after
administration of the drug. No phosphorylation products
were found before administration.
Intracellular concentrations of AZT-MP after 1-2 h were
0.9-1.4 pmol/l 06 PBMC and then declined to 0.3-1.1
pmol/Iu" PBMC after 4 h. AZT-DP and AZT-TP reached
concentrations of 0.3-0.5 pmolj I 06 PBMC after 1-2 hand
could not be detected after 4 h in any of the three patients
(table 2).
Discussion
Quantification of intracellular AZT nucleotides has so far
been done only in cell cultures treated with [3H]AZT [2,
7-9]. Since radiolabeling is not feasible in human pharmaco-
kinetic studies, a method was developed that uses the selectiv-
ity ofHPLC to separate mono-, di-, and triphosphate and the
sensitivity of a commercially available RIA to quantify them
in PBMC obtained from patients treated with AZT.
Cell extracts contain large amounts of natural ribonucleo-
tides, which in part coelute with AZT nucleotides in HPLC.
They were destroyed by periodate oxidation [12] to limit
potentially cross-reacting contaminations of RIA samples.
Alkaline phosphatase activity is inhibited by inorganic phos-
phates present in the elution buffer. Large amounts of the
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Table 2. Phosphorylation of zidovudine (AZT) in three patients
receiving 250 mg every 12 h.
Plasma AZT
Patient. h (umol/I) AZT-MP AZT-DP AZT-TP
1,0 <0.03 <0.1 <0.1 <0.1
I 2.22 1.2 0.3 0.2
2 0.72 1.4 0.3 0.3
4 0.25 1.1 <0.1 <0.1
2, 0 <0.03 ND NO ND
I 2.98 0.9 0.3 0.3
2 0.61 0.6 0.2 0.2
4 0.10 0.3 <0.1 <0.1
3,0 <0.03 <0.1 <0.1 <0.1
I 0.81 0.7 <0.1 0.2
2 2.17 1.1 0.5 0.5
4 0.77 1.0 <0.1 <0.1
NOTE. Values are means of duplicate determinations that deviated by <20%.
AZT-MP (monophosphate), -OP (diphosphate), and -TP (triphosphate) concen-
trations are given in pmol/ I06 peripheral blood mononuclear cells. NO = not
done.
enzyme and long incubation times are therefore required to
obtain equimolar amounts of AZT from AZT-MP, -DP, and
-TP. Recovery experiments showed the feasibility of our ap-
proach (table 1). AZT-TP concentrations found were always
slightly above the expected value. Considering multiple sam-
ple manipulations and the lack ofan internal standard, accu-
racy appears satisfactory.
Since the cell membrane is partly permeable for AZT-MP
[13], and isolation of PBMC from whole blood takes r-., 1 h,
we suspected a partial loss of intracellular AZT-MP may oc-
cur. However, no change in AZT-MP concentration and no
hydrolysis of AZT-TP was observed when [3H]AZT-labeled
PBMC were harvested from cell cultures by ficoll-hypaque
separation. Analyzing AZT nucleotide pools of PBMC
grown in the presence of [3H]AZT or AZT by either HPLC
and liquid scintillation counting or HPLC-RIA yielded com-
parable results. AZT-TP concentrations measured in patient
cells suggest a rapid decay in vivo (table 2). This contrasts
with an in vitro study [7] using a leukemic T cell line in
which an intracellular half-life for AZT-TP of200 min was
observed. A possible explanation may be the finding by Bal-
zarini et al. [8] that intracellular metabolism ofAZT is highly
dependent on the cell species [8].
Stretcher et al. [14, IS] measured the concentration of
total phosphorylated AZT (i.e., AZT-MP, -DP, and -TP) in
PBMC ofpatients receiving AZT at a dose of500 mg/day. In
14 samples obtained from 12 patients at various time points,
concentrations of 0.3-4 pmol/ 106 cells were found. Pooled
data from that population showed no decrease in total phos-
phorylated AZT over 3.5 h so the authors concluded that the
decay of phosphorylated AZT was slow. Nevertheless, since
AZT-MP is the most abundant phosphorylation product and
the ratio between mono- and triphosphate appears incon-
stant (table 2), changes in the AZT-TP concentration will
not necessarily be detected by that assay.
Assuming a mean cellular volume of0.25 pl, the detection
limit of O. I pmol/ 106 PBMC corresponds to an intracellular
concentration of 0.4 Jlmol/l. Data from various studies indi-
cate that AZT-TP may affect viral transcription at concentra-
tions below the detection limit ofour assay. Competitive inhi-
bition of human immunodeficiency virus type 1 reverse
transcriptase (HIV-RT) by AZT-TP has been studied by sev-
eral groups [2-4]. Depending on the primer template used,
K, values ranging from 0.01 umcl/l (for HIV RNA) to 0.3
umol/I (for activated calf thymus DNA) were reported,
which suggests that considerable inhibition of HIV -R T oc-
curs even at concentrations < 0.4 Jlmol/l.
Huang et al. [5] studied the incorporation of AZT-TP into
a DNA primer by HIV-RT in vitro. They observed termina-
tion ofprimer elongation even when the AZT-TP concentra-
tion was 0.3 Jlmolfl, l Ofl-fold less than that of thymidine
5'-triphosphate.
The data from this pilot study with three patients show
that AZT nucleotides in PBMC can be measured with our
method. Currently the assay is laborious and requires blood
volumes that make frequent sampling unacceptable. Further
modifications may improve its sensitivity and facilitate de-
tailed studies of intracellular AZT nucleotide pharmaco-
kinetics.
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